These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 26152725

  • 1. Human Epidermal Growth Factor Receptor 2 (HER2) Impedes MLK3 Kinase Activity to Support Breast Cancer Cell Survival.
    Das S, Sondarva G, Viswakarma N, Nair RS, Osipo C, Tzivion G, Rana B, Rana A.
    J Biol Chem; 2015 Aug 28; 290(35):21705-12. PubMed ID: 26152725
    [Abstract] [Full Text] [Related]

  • 2. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
    Xia W, Petricoin EF, Zhao S, Liu L, Osada T, Cheng Q, Wulfkuhle JD, Gwin WR, Yang X, Gallagher RI, Bacus S, Lyerly HK, Spector NL.
    Breast Cancer Res; 2013 Aug 28; 15(5):R85. PubMed ID: 24044505
    [Abstract] [Full Text] [Related]

  • 3. Mixed lineage kinase 3 and CD70 cooperation sensitize trastuzumab-resistant HER2+ breast cancer by ceramide-loaded nanoparticles.
    Kumar S, Das S, Sun J, Huang Y, Singh SK, Srivastava P, Sondarva G, Nair RS, Viswakarma N, Ganesh BB, Duan L, Maki CG, Hoskins K, Danciu O, Rana B, Li S, Rana A.
    Proc Natl Acad Sci U S A; 2022 Sep 20; 119(38):e2205454119. PubMed ID: 36095190
    [Abstract] [Full Text] [Related]

  • 4. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
    Tanizaki J, Okamoto I, Fumita S, Okamoto W, Nishio K, Nakagawa K.
    Oncogene; 2011 Sep 29; 30(39):4097-106. PubMed ID: 21499301
    [Abstract] [Full Text] [Related]

  • 5. Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells.
    Hosonaga M, Arima Y, Sugihara E, Kohno N, Saya H.
    Cancer Sci; 2014 Jul 29; 105(7):779-87. PubMed ID: 24754246
    [Abstract] [Full Text] [Related]

  • 6. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.
    O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, Crown J, O'Donovan N, Slamon DJ.
    Mol Cancer Ther; 2010 Jun 29; 9(6):1489-502. PubMed ID: 20501798
    [Abstract] [Full Text] [Related]

  • 7. Estrogen suppresses MLK3-mediated apoptosis sensitivity in ER+ breast cancer cells.
    Rangasamy V, Mishra R, Mehrotra S, Sondarva G, Ray RS, Rao A, Chatterjee M, Rana B, Rana A.
    Cancer Res; 2010 Feb 15; 70(4):1731-40. PubMed ID: 20145118
    [Abstract] [Full Text] [Related]

  • 8. Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways.
    Niu G, Carter WB.
    Cancer Res; 2007 Feb 15; 67(4):1487-93. PubMed ID: 17308086
    [Abstract] [Full Text] [Related]

  • 9. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.
    Asanuma H, Torigoe T, Kamiguchi K, Hirohashi Y, Ohmura T, Hirata K, Sato M, Sato N.
    Cancer Res; 2005 Dec 01; 65(23):11018-25. PubMed ID: 16322251
    [Abstract] [Full Text] [Related]

  • 10. Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.
    Nencioni A, Cea M, Garuti A, Passalacqua M, Raffaghello L, Soncini D, Moran E, Zoppoli G, Pistoia V, Patrone F, Ballestrero A.
    PLoS One; 2010 Feb 02; 5(2):e9024. PubMed ID: 20126311
    [Abstract] [Full Text] [Related]

  • 11. Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway.
    Way TD, Kao MC, Lin JK.
    J Biol Chem; 2004 Feb 06; 279(6):4479-89. PubMed ID: 14602723
    [Abstract] [Full Text] [Related]

  • 12. Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.
    Fujimoto Y, Morita TY, Ohashi A, Haeno H, Hakozaki Y, Fujii M, Kashima Y, Kobayashi SS, Mukohara T.
    Sci Rep; 2020 Dec 10; 10(1):21762. PubMed ID: 33303839
    [Abstract] [Full Text] [Related]

  • 13. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
    Yao E, Zhou W, Lee-Hoeflich ST, Truong T, Haverty PM, Eastham-Anderson J, Lewin-Koh N, Gunter B, Belvin M, Murray LJ, Friedman LS, Sliwkowski MX, Hoeflich KP.
    Clin Cancer Res; 2009 Jun 15; 15(12):4147-56. PubMed ID: 19509167
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A functional comparison between the HER2(high)/HER3 and the HER2(low)/HER3 dimers on heregulin-β1-induced MMP-1 and MMP-9 expression in breast cancer cells.
    Kim S, Han J, Shin I, Kil WH, Lee JE, Nam SJ.
    Exp Mol Med; 2012 Aug 31; 44(8):473-82. PubMed ID: 22627808
    [Abstract] [Full Text] [Related]

  • 17. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
    Takeda T, Yamamoto H, Kanzaki H, Suzawa K, Yoshioka T, Tomida S, Cui X, Murali R, Namba K, Sato H, Torigoe H, Watanabe M, Shien K, Soh J, Asano H, Tsukuda K, Kitamura Y, Miyoshi S, Sendo T, Toyooka S.
    PLoS One; 2017 Aug 31; 12(2):e0171356. PubMed ID: 28158234
    [Abstract] [Full Text] [Related]

  • 18. Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells.
    Le XF, Arachchige-Don AS, Mao W, Horne MC, Bast RC.
    Mol Cancer Ther; 2007 Nov 31; 6(11):2843-57. PubMed ID: 18025271
    [Abstract] [Full Text] [Related]

  • 19. Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.
    Ferreira RB, Wang M, Law ME, Davis BJ, Bartley AN, Higgins PJ, Kilberg MS, Santostefano KE, Terada N, Heldermon CD, Castellano RK, Law BK.
    Oncotarget; 2017 Apr 25; 8(17):28971-28989. PubMed ID: 28423644
    [Abstract] [Full Text] [Related]

  • 20. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
    Park SH, Ito K, Olcott W, Katsyv I, Halstead-Nussloch G, Irie HY.
    Breast Cancer Res; 2015 Jun 19; 17(1):86. PubMed ID: 26084280
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.